Vandria, a Lausanne, Switzerland-based mitochondrial therapeutics company developing small molecule mitophagy inducers, raised $20.6M in Series A funding.
The round was led by ND Capital together with a small syndicate of HNW private investors.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Klaus Dugi, CSO Penelope Andreux and Head of BD & Finance Peter Harboe-Schmidt, Vandria is a mitochondrial therapeutics company developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer which has been shown to acutely improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. VNA-318 is expected to enter the clinic in Q2 2024.
The company is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases. A separate program targets ferroptosis, a form of cell death implicated in neurodegenerative diseases and ischemia reperfusion injury.
FinSMEs
14/12/2023